Company: PTPI
Filing Date: 2025-02-13
Form Type: S-1/A
Source: 0001410578-25-000122
Chunk: 3

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-13
Form: S-1/A
Chunk 3
---
 additional stockholder meeting to be held every ninety days thereafter until (i) such Stockholder Approval is obtained, or (ii) December 31, 2025, whichever is sooner. We cannot assure you that we will be able to obtain requisite Stockholder Approval.The Series B Preferred Stock will become convertible beginning on the first trading day following the date on which we publicly announce through the filing of a Current Report on Form 8-K that the amendment to our Charter to sufficiently increase our authorized shares of common stock to cover the conversion of all outstanding shares of Series B Preferred Stock into common stock has been filed with the Secretary of State of the State of Delaware (the “Initial Conversion Date”), at which time, each share of the Series B Preferred Stock will be convertible into 1,000 shares of common stock. In the event our stockholders do not approve the Charter Amendment, the Series B Preferred Stock will not be convertible into common stock and the value of the Series Warrants and the Series B Preferred Stock may be negatively affected. See the Risk Factor on page 12 relating to the Series B Preferred Stock and Stockholder Approval, and see the section entitled “Stockholder Approval” on page 57 for additional details regarding the Stockholder Approval.This prospectus also relates to the offering of the shares of Series B Preferred Stock issuable upon the exercise of the Series Warrants, including up to 223,048.326 shares of Series B Preferred Stock issuable in connection with a Series B Warrant
The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and the Company is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.

holder’s exercise of an “alternative cashless exercise” feature described below and up to 74,349.442 shares of Series B Preferred Stock issuable upon exercise of the Series A Warrants.

The Units have no stand-alone rights and will not be certificated or issued as stand-alone securities. Each Series A Warrant offered hereby will become exercisable immediately at an exercise price of $ per share of Series B Preferred Stock and will expire on the 5 year anniversary of the Initial Conversion Date. Each Series B Warrant offered hereby will become exercisable immediately at an exercise price of $ per share of Series B Preferred Stock and will expire on the one (1) year anniversary of